USA flag logo/image

An Official Website of the United States Government

IN VITRO ANTINEOPLASTIC DRUG TOXICOLOGY CHARACTERIZATION

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
13741
Program Year/Program:
1992 / SBIR
Agency Tracking Number:
13741
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Hipple Cancer Research
4100 S Kettering Boulevard Dayton, OH 45439
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1992
Title: IN VITRO ANTINEOPLASTIC DRUG TOXICOLOGY CHARACTERIZATION
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

THE CLINICAL UTILITY OF MANY ANTICANCER AND ANTI-HIV DRUGS IS FREQUENTLY LIMITED BY THEIR SERIOUS TOXICITIES, MYELOTOXICITY BEING THE MOST COMPROMISING DOSE-LIMITING COMPLICATION. FURTHERMORE, ALL PRECLINICAL DRUG TOXICOLOGY IS PERFORMED IN VIVO, WHICH IS OFTEN VERY COSTLY AND TIME CONSUMING. THIS PHASE I PROJECT HAS DEVELOPED ASSAYS THAT BETTER CHARACTERIZE AND PROBE THE MYELOTOXICITY OF ANTICANCER AND ANTI-HIV AGENTS. BECAUSE THESE ASSAYS UTILIZE NORMAL HUMAN MARROW, THEY ARE DESIGNED TO BE OF DIRECT CLINICAL RELEVANCE. PHASE I EFFORTS EXPLOITED THE AVAILABILITY OF RECOMBINANT HEMATOPOIETIC REGULATORY FACTORS TO STANDARDIZE IN VITRO HUMAN AND MURINE BONE MARROW PROGENITOR ASSAYS. THESE ASSAYS HAVE BEEN USED TO QUANTITATE THE PRECLINICAL HEMATOTOXICITIES OF KNOWN ANTICANCER AND ANTI-HIV DRUGS. A CORRELATION BECAME EVIDENT BETWEEN THE IN VITRO HEMATOTOXICITY AND KNOWN IN VIVO MYELOTOXICITIES IN MICE. DIRECT EVIDENCE HAS BEEN OBTAINED VALIDATING THE ABILITY OF THE IMPROVED IN VITRO HEMATOPOIETIC ASSAY TO PREDICT MYELOTOXICITY IN VIVO. IN PHASE I, THE FEASIBILITY OF SUCH AN IN VITRO/IN VIVO PROTOCOL USING DRUGS WHOSE IN VITRO AND IN VIVO MYELOTOXICITIES ARE WELL ESTABLISHED WAS DOCUMENTED. HAVING ESTABLISHED THE FEASIBILITY OF THIS IMPROVED SYSTEM, INVESTIGATIONAL NEW DRUGS WILL BE EXPLORED IN PHASE II.

Principal Investigator:

Martin J Murphy Jr
5132997120

Business Contact:

Small Business Information at Submission:

Hipple Cancer Research Corp.
4100 S Kettering Blvd Dayton, OH 45439

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No